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doi:10.1016/j.seizure.2005.02.004ummary The aim of this multicentric, prospective and uncontrolled study was to
valuate the efficacy and safety of levetiracetam in 110 children with refractory
pilepsy, of whom 21 were less than 4 years old. After a median follow-up period of 7
onths, levetiracetam administration was effective (responders with >50% decrease
n seizure frequency) in 39% of children, of whom 10 (9%) became seizure-free. The
fficacy was higher in patients with localization-related epilepsy (58% of responders)
han in those with generalized epilepsy (37% of responders). Levetiracetam was well
olerated. The main side effects of somnolence and irritability occurred in 14% of
atients. In one patient acute choreoathetosis occurred after few doses of levetir-
cetam. Overall, the adverse effects were not severe. Children younger than 4 years
ere particularly tolerant. In conclusion, the present study confirms that levetir-
cetam is effective and well tolerated as an add-on treatment in children with
efractory epilepsy. Our preliminary data also indicate that levetiracetam may be a
alid therapeutic option for epilepsy in infants and young children.
2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Levetiracetam (LEV) is one of the latest antiepilep-
tic drugs (AED) available on the market for treating
drug resistant partial epilepsy in adults.1 Mechan-7586 522;
Balestri).
5 BEA Trading Ltd. Publishedisms underlying its antiepileptic activity are still
incompletely understood. The pharmacokinetic pro-
file of LEV, which is characterised by its rapid and
almost complete absorption after oral administra-
tion, linear pharmacokinetics, minimal protein
binding and predominantly renal excretion, makes
the drug a good option for the treatment of pae-
diatric patients.2 However, although double-blind
placebo-controlled clinical trials and uncontrolledby Elsevier Ltd. All rights reserved.
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adults,3—10 only a few studies have examined the
usefulness of this drug in treating childhood epi-
lepsy.10 In particular, with the exception of a few
reports,11—18 it is still necessary to establish the
efficacy of LEV for epilepsy syndromes. Indeed, most
studies have evaluated the efficacy of LEV in rela-
tion to seizure type.11
Here we report on a multicentric, prospective,
uncontrolled study undertaken to acquire further
information about efficacy and toleration of LEV
in a paediatric population with refractory epilepsy
syndromes.Table 1 Etiologic findings of patients.
Etiologies N
Symptomatic
Post-anoxia-ischemia 21
Brain malformations 12
Post-infectious 7
Chromosome anomalies 3
Cryptogenic 67Patients and methods
Study design
This was an open, multicentric, prospective, prag-
matic study reflecting normal clinical practice when
the decision is made to add a new antiepileptic drug
to those already prescribed for a child with refrac-
tory seizures. Seizure frequencies, type and dura-
tion were recorded by parents and caregivers over a
6-month period before starting treatment with LEV.
The drug was administered at a daily dose of 5 mg/
kg, given in two or three equal doses per day, with
the dose increasing every week up to a maximum of
60 mg/kg per day. If adverse reactions occurred, the
titration phase was extended on the basis of clinical
information. In all patients, general clinical neuro-
logical examinations and EEGs were performed at
inclusion and after a minimum of 8 weeks. There-
after, neurological examination and EEGs together
with complete peripheral blood counts, urinary
analysis and measurement of blood creatinine, ala-
nine and aspartate aminotransferase levels were
performed every 3 months. However, in three
patients a follow-up period of 2 months only was
available.
Patients
From January 2001 to December 2003, 110 children
(52 girls and 60 boys) under 16 years receiving LEV
were recruited from five centres in Italy. The mean
age at enrolment was 7.7 years (range 6 months to
15.9 years). Of the 110 patients, 21 (19%) were less
than 4 years old. Patients with progressive neuro-
logical disorders were excluded from the study.
Family and personal histories were taken and neu-
rological examinations performed on all patients.
Electroencephalograms (EEGs) were recorded dur-
ing wakefulness, spontaneous sleep and arousal,
with hyperventilation and photic stimulation in sub-jects that gave sufficient collaboration. Long-term
video EEG was performed when it was considered
useful for classifying the type of epilepsy. All
patients underwent imaging studies with brain mag-
netic resonance imaging (MRI). Biochemical ana-
lyses, chromosomal investigations and screening
for metabolic disorders were carried out in all
patients. Seizure types and epilepsy syndromes
were classified in accordance with the International
League Against Epilepsy (ILAE) classifications.19—21
Intelligence quotient (IQ) was evaluated by the
Brunet-Le´zine test and WISC-R, according to the
patient’s age. Mental retardation was present in
81 patients (74%) and considered severe in 45,
moderate in 19, and mild in 17. Median seizure
frequency was 22 seizures/month (range 4—129).
Mean age at the first seizure was 2.6 years (range
0.5—13 years). The mean duration of epileptic his-
tory was 6.4 years (range 0.6—15 years). Epilepsy
was symptomatic in 43 patients (39%) and crypto-
genic in 67 (61%) (Table 1). In 28 patients (25%),
partial seizures had a secondary generalization.
Epilepsy was related to localization (LRE) in 53
patients (48%), generalized in 45 (41%) and unclas-
sifiable in 12 (11%) (Table 2). Specifically, patients
less than 4 years old were affected by LRE13 and
generalized epilepsy.8 Informed consent for LEV
administration was obtained from the parents. A
mean of seven (range 2—12) AEDs were tried before
introducing LEV treatment. The number of AEDs
administered when LEV treatment began ranged
from one to five (median two); 29 patients (26%)
received one AED, 57 patients (52%) two AEDs, 18
(16%) three AEDs and six (5%) more than three AEDs.
Drugs administered at the start of LEV therapy
included valproate (46%), carbamazepine (37%),
vigabatrin (27%), topiramate (26.5%), clonazepam
(24.5%), lamotrigine (18.5%), chlormethyldiazepam
(9%) and phenobarbital (5%).
Response
Comparedwith baseline seizure frequency and sever-
ity, the response to LEV treatment was classified as:
complete cessation (100% seizure control); very good
(seizure frequency decreased by 50—99%); minimal
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Table 2 Efficacy of LEV according to epilepsy syndromes.
Epilepsy syndromes Number of patients Responders/seizure-free
Localization related epilepsy 53 25/6
Cryptogenic (22) (12/5)
Symptomatic (31) (13/1)
Generalized 45 16/4
Myoclonic-astatic epilepsy (6) (4/1)
Dravet’s syndrome (6) (2/0)
Cryptogenic generalized (4) (2/1)
Infantile spasms (5) (1/0)
Ohtahara syndrome (2) NR
Lennox-Gastaut (8) (2/0)
Startle epilepsy (3) (2/1)
Symptomatic generalized (11) (3/1)
Unclassifiable 12 2/0
NR: Unresponsive.(seizure reduction to less than 50% with minimal
change in seizure severity); unmodified (seizure
reduction less than 20%) or worse (increase in seizure
frequency). We defined responders those patients
who at the last follow-up visit had more than 50%
reduction in seizure frequency during a minimum
period of 8 weeks. Efficacy was evaluated in accor-
dance with the type of epilepsy syndrome and age
before LEV treatment. The presence of adverse
events was obtained from parents at each control.
Statistical evaluations
Levels of significance were calculated using Fisher’s
exact test, ANOVA and the two-tailed Wilcoxon rank
sum test for non-parametric data.Results
Clinical follow-up ranged from 2 to 20 months (med-
ian 7.6). LEV dosages varied from 10 to 60 mg/kg per
day (median 38  4.1).
Efficacy
Forty-five patients (41%) remained on LEV therapy
at the latest follow-up. In the remaining 65 patients,
administration of the drug was tapered off because
of inefficacy. Specifically, 10 children (9%) became
seizure-free, 33 (30%) had a seizure reduction of
more than 50%, and 27 (24.5%) had aminimal seizure
reduction. In a further 28 patients (25%) seizure
frequency remained unchanged, whereas 12 (11%)
experienced an increase in seizure frequency.
Therefore, 43 patients (39%) were considered posi-
tive responders in that they had a greater than 50%
reduction in seizure frequency. In two patients, LEVtherapy was continued because they became more
alert. In relation to the type of epilepsy, LEV
appeared more effective in LRE (58% of responders)
than in generalized epilepsy (37% of responders).
Among patients with LRE, the highest responder
rates were in patients with cryptogenic partial sei-
zures (Table 2). Of the patients with generalized
epilepsy, responders were observed in the group
exhibiting myoclonic-astatic epilepsy (4/6), gener-
alized symptomatic epilepsy (3/11), generalized
cryptogenic epilepsy (2/4), Dravet syndrome (2/
6), Lennox-Gastaut syndrome (2/8), and infantile
spasms (1/5). Two out of three patients with startle
epilepsy were responsive to LEV. Two responders
(14%) were also observed among the patients having
an unclassifiable epilepsy syndrome (Table 2). In two
patients affected by localization-related epilepsy,
LEV monotherapy was considered successful
because one was seizure-free after 6 months and
the other after 9 months. In a further 24 children
(22%), one or more concomitant drugs were tapered
off or the doses reduced without affecting seizure
frequency. Patients with a short history of epilepsy
(less than 3 years) were more likely to become
responders than were those whose epilepsy history
was more than 3 years (P = 0.049).
Patients younger than 4 years had a higher pro-
portion of responders compared with older patients
(57 and 35%, respectively). Specifically, eight
patients in this group with LRE (61%) and four
(50%) with generalized epilepsy could be classified
as responders (Fig. 1). However, the population size
was too small for statistical analysis.
Safety
Adverse reactions occurred in 16 patients (14% of
the total entering the study). The most frequently
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Figure 1 Comparison of responsiveness by epilepsy type
and patient age (n = 98). On the left are reported patients
aged less than 4 years, on the right the older ones.
Responders: patients with seizure frequency decreased
by 50—100%; no responders: patients with minimal/unmo-
dified variation of seizure frequency; LRE: localization
related epilepsy.reported treatment-related side effects were drow-
siness12 and nervousness.3 In two patients, treat-
ment was discontinued because of adverse side
effects. Another patient, who had been seizure-free
after a few days of LEV treatment (5 mg/kg per
day), developed severe acute choreoatethosis,
which forced us to taper off the drug. After a few
days, a second attempt at LEV introduction was
again followed by a relapse of choreoatethosis.
LEV was therefore completely suspended and the
adverse reaction disappeared. However, when con-
sidered over all patients, the side effects were mild
in severity. Moreover, in 19 patients (17%), LEV was
reported to have beneficial effects in addition to
seizure reduction. These patients became ‘‘better
behaved’’ and demonstrated increased levels of
concentration. There were no significant anomalies
in the laboratory results of liver function, renal
function or haematological criteria.Discussion
Controlled and open-label studies have demon-
strated the efficacy of LEV for a wide range of
seizures and epilepsies. LEV has been shown to be
effective in children and adults with partial epi-
lepsy.3,4,6—9,11—13 In this context, Glauser et al.
found that 52.5% of paediatric patients with partial
seizures were responsive to LEV, with more than 50%
showing seizure reduction.12,13 LEV was also effec-
tive in three patients with BECTS.22 Although anec-
dotal data has demonstrated LEV efficacy in
generalized epilepsy in childhood,most studies have
evaluated LEV efficacy in refractory epilepsy syn-dromes, including children suffering from both gen-
eralized and partial epilepsy. In a retrospective open
study, Herranz et al. found responders (those with
more than 50% seizure frequency reduction) in 43
(65%) of children with both focal and generalized
seizures.14,15 Lower responder rates (47%) were
found by Lagae et al. in open-label add-on study
that included 21 children affected by highly refrac-
tory epilepsy11 and by Wheless and Ng who observed
a 33.3% responder rate in 39 children with refractory
epilepsy.16 LEV has been effective in Lennox-Gas-
taut syndrome, in which the drug was found to be
effective against myoclonic seizures and tonic-clo-
nic seizures rather than atypical absences.11,17
Lagae et al. have also underlined the positive effect
of LEV on myoclonic seizures.11 Anecdotal data
reported LEV effectiveness in patients with
Landau-Kleffner syndrome23 and CSWS24 as well as
in some non-epileptic disorders such as spinal myo-
clonus.25 Moreover, LEV has been shown to reduce
hyperactivity, impulsivity, mood instability and
aggression in autistic children.26
The present study only included patients with
refractory epilepsy. All patients were under several
therapeutic regimens when LEV treatment was
begun. According to Lagae et al., the cardinal goal
of add-on treatment in such patients is not for them
to be seizure-free, which remains difficult, but to
improve their quality of life by decreasing seizure
frequency as much as possible while limiting adverse
reactions.11 In the present study, LEV efficacy was
evaluated in relation to epilepsy syndromes rather
than to seizure types. Indeed, it is known that the
same type of seizure may be more or less responsive
to an AED in accordance with the epilepsy syndrome
in which it occurs, and that this is particularly true in
children, who may be affected by a wide spectrum
of epileptic syndromes.27 In summary, 39% of
patients had a more than 50% reduction in seizure
frequency after a median follow-up period of 7
months. The percentage of responders was lower
than that reported by Herranz14,15 and by Lagae
et al.,11 but was in agreement with that reported
by Wheless and Ng.16 As in the previous studies, we
observed a higher responder rate among patients
with LRE (58% of responders) than in those affected
by generalized epilepsy (37% of responders). In
particular, four out of six with myoclonic-astatic
epilepsy and two out of eight patients with Len-
nox-Gastaut were responders. In contrast, only one
patient among five with infantile spasms, showed a
significant reduction in seizure frequency. However,
because all the patients had very refractive sympto-
matic infantile spasms, we believe that further
investigations are needed to establish the real effi-
cacy of LEV for this epilepsy syndrome. It is inter-
252 S. Grosso et al.esting to note the effectiveness of LEV in the two
patients with startle epilepsy, one of whom had
been seizure-free for 3 months at follow-up. In
general terms, we noted that LEV was more effec-
tive in children who had a short history of epilepsy
(less than 3 years) than in those with a longer
history.
In the present study, we have also evaluated LEV
efficacy in children less than 4 years old. There are
few data available in the literature on the efficacy
and tolerability of LEV in such a population. Our
preliminary data suggest that LEV may be effective
in controlling epilepsy in infants and young children.
In fact, although it was not possible to perform a
statistical analysis, responder rates were higher in
younger than in older children. Of course, these
findings need to be confirmed by further clinical
studies.
As in a previous clinical investigation,11,16 we also
observed that the effect of LEV may be seen in some
patients during the first weeks after starting the
drug. Indeed, four children became seizure-free
after a mean period of 18 days at a mean dosage
of 14 mg/kg per day. All of them were affected by
cryptogenic LRE. This phenomenon was not
observed in children with generalized epilepsy.
With regard to safety, LEV has been reported to
be a well-tolerated drug. Adverse reactions, mainly
represented by headache, infection, somnolence
and anorexia, have been reported, with the inci-
dence varying from 1012,13 to 19%.11 Acute psychosis
has also been reported.14,28—30 It seems that side
effects occur chiefly in those patients taking high
LEV doses (>40 mg/kg per day).11,14 In the present
study, side effects such as somnolence and irritabil-
ity were observed in 16 patients (14%). However,
acute choreoatethosis, which has never been
described before, occurred in one patient, forcing
us to taper-off the drug in spite of complete seizure
control. LEV was also discontinued in two other
patients suffering from drowsiness and irritability.
However, when globally evaluated, adverse reac-
tions were consideredmild in severity and transient.
It is interesting that, with the exception of the
patient showing acute choreoathetosis, no child
of less than 4 years showed severe side effects
related to LEV therapy. This seems to indicate that
the drug is safe in young children and infants.Conclusion
The present study demonstrated that LEV may be
effective in a wide range of refractory epilepsy
syndromes, even when administered before the
age of 4 years. Therefore, although comparativestudies of other new AEDs used as add-ons are
necessary, we believe that LEV may be considered
a valid and safe therapeutic option in children with
refractory epilepsy syndromes.References
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